HOME >> BIOLOGY >> NEWS
A tumour suppressor in mice and men

Prof. Reinhard Fässler, showed that the transcription factor is helped by a molecular "ticket".

Large numbers of ubiquitin molecules can be attached in sequence to proteins. A certain kind of binding marks this protein as "rubbish" which has to be removed. Another type of ubiquitin attachment to proteins functions as a kind of transport signal. It negotiates the transfer, for example, of proteins into the nucleus. The study shows that this is the case with Bcl-3. It only functions like this, however, when Cyld does not get in the way. This protein was first found in patients suffering from cylindromas. These are tumours that grow on the face, neck, and scalp. Cyld is a deubiquitinase - an enzyme that removes ubiquitin groups from other proteins. "We could show in our study that Cyld proteins can accumulate around the nucleus," says Fässler. "They can intercept Bcl-3 there and prevent it from being imported into the nucleus, by removing ubiquitin appendages." This is the first evidence ever of a specific mechanism that regulates and controls the Bcl-3 oncogene.

The team of researchers from Munich flawlessly reconstructed Cyld interaction with Bcl-3. They demonstrated every step in the process, from the recruiting of Cyld over to the nuclear membrane, to the ubiquitinisation of Bcl-3, and Cyld's reversal of this process. They also showed in detail that Bcl-3 collects without Cyld in the nucleus, and can cause cell proliferation with p50 and p52. All in all, it seems not unlikely that Cyld functions as a tumour suppressor in mice and in humans. In humans, there is evidence that a defective Cyld gene can have negative consequences, like the largely benign tumours of cylindromas. The researchers also found very little, or no, Cyld in the cells of other skin tumours. The situation is similar in some cases of liver, kidney, and uterine cancer. "Cyld is expressed in every cell in the body", Fässler says. "I believe personally that the deubiquitinase activit
'"/>

Contact: Eva-Maria Diehl
diehl@biochem.mpg.de
49-898-578-2824
Max-Planck-Gesellschaft
29-May-2006


Page: 1 2 3

Related biology news :

1. Research team develops cancer-curing T-lymphocyte-based therapy to eradicate malignant tumours
2. Sick Kids researchers confirm that cancer stem cells initiate and grow brain tumours
3. Multicenter study nets new lung tumor-suppressor gene
4. MicroRNAs can be tumor suppressors
5. MicroRNAs as tumor suppressors
6. Novel regulation of the common tumor suppressor PTEN
7. Tumor-suppressor gene is critical for placenta development
8. Novel regulatory mechanism identified for key tumor suppressor p53
9. A tumor suppressor that promotes cancer cell growth?
10. Structure determined for p53 tumor suppressor protein as bound to DNA for anti-cancer activity
11. Mutation in tumor suppressor gene causes pancreatic islet cells to reproduce

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/28/2017)... BARCELONA , Spanien, 27. Februar 2017 /PRNewswire/ ... durch Iris-Scan, wird seine erstklassige biometrische Lösung ... Snapdragon™ 835 mit X16 LTE auf dem ... 2. März) am Qualcomm-Stand in Halle 3, ... 835-Prozessor beinhaltet die Sicherheitsplattform Qualcomm Haven™ – ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):
(Date:3/28/2017)... WASHINGTON , March 28, 2017 /PRNewswire/ ... launch single-cell sequencing during the American Association for Cancer ... Convention Center in Washington, D.C. , ... differential gene expression of thousands of cells at the ... Experts on-hand at AACR to discuss ...
(Date:3/28/2017)... 28, 2017 Biostage, Inc. (Nasdaq: ... bioengineered organ implants to treat cancers and other life-threatening ... that Jim McGorry, CEO of Biostage, will ... panel at the MassBio 2017 Annual Meeting ... in Cambrige, Massachussetts. The 3D Printing and BioEngineering ...
(Date:3/28/2017)... March 28, 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) ... report compelling safety and clinical data from its phase 1/2 ... collagen-expressing, hair follicle-derived fibroblasts (RCT-01) as a treatment for Achilles ... ... complete safety profile at 6 months and showed no serious ...
(Date:3/27/2017)... Cousins Properties (NYSE: CUZ ) announced today that ... a 10-year, approximately 125,000 square-foot lease at Corporate Center, a ... Westshore submarket of Tampa, FL. ... Center for their new location in Tampa ... officer of Cousins Properties. "Amgen is a cutting-edge global company ...
Breaking Biology Technology:
Cached News: